Ozempic Neck (Turkey Neck After Weight Loss): Causes and What Helps

Start with our pillar guide: How to Fix Ozempic Face: What the Evidence Supports (2026), or browse all GLP-1 & Skin articles.

Ozempic neck is an informal term for looser, crepier neck and jawline skin after weight loss on semaglutide or tirzepatide. Weight-loss studies show neck fat shrinks, but no study we found has measured the neck in GLP-1 users, and no topical product has been tested in them. Evidence: limited (indirect, from diet and bariatric-surgery studies).

Key takeaways

• Ozempic neck is a weight-loss effect, not a diagnosis. In an 18-month diet trial of 278 adults, neck fat fell 13.1% at 6 months (Tsaban et al., 2021). No equivalent study exists in GLP-1 users.
• The neck doesn't respond the same way in everyone. After bariatric surgery, total weight lost did not significantly predict how much neck volume people lost (n=23) (Peters et al., 2020).
• No human study shows semaglutide or tirzepatide directly damages skin collagen. The skin-biopsy data come from people who lost weight after bariatric surgery.
• No topical product, peptides included, has been tested in GLP-1 users. Neck-specific skincare studies were done in people who weren't on these drugs.
• Injectable treatment data are thin. The largest GLP-1-specific study (n=41) treated cheeks and jawline, had no control group and was funded by the product's maker (Lorenc et al., 2026).

Never stop, skip or change a GLP-1 medication for skincare reasons. Talk to your prescriber first.

The neck is one part of a wider set of changes covered in our guide to what causes Ozempic face and what can help. This article sticks to the neck and jawline: what research has actually measured, what it hasn't, and where the online advice outruns the data.

What is Ozempic neck?

Ozempic neck is a nickname, not a medical condition. It describes visible neck and jawline changes (loose skin, a softer jaw contour, horizontal creases, crepey texture or more prominent vertical neck bands) that some people notice after substantial weight loss on GLP-1 medications.

GLP-1 receptor agonists are drugs that mimic a gut hormone involved in appetite and blood sugar. They include semaglutide (Ozempic, Wegovy) and the dual GLP-1/GIP agonist tirzepatide (Mounjaro, Zepbound). These drugs can produce a lot of weight loss. In the STEP 1 trial, a randomized controlled trial (RCT) sponsored by Novo Nordisk, adults on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks (Wilding et al., 2021). The STEP 3 trial, which added intensive behavioral therapy, reported 16.0% (Wadden et al., 2021). Evidence: well-established for weight loss.

The same neck changes appear after weight loss from any cause. A 2024 systematic review of 13 studies plus 1 abstract on surgical and medical weight loss linked massive weight loss with facial aging, including mid-cheek volume loss and central neck skin laxity, meaning loose skin that has lost its firmness (Jafar et al., 2024). Funding was not reported in the abstract. Evidence: limited (observational studies).

What causes Ozempic neck?

Ozempic neck appears to come from losing the fat that sits under neck and jaw skin, while the skin itself doesn't shrink back right away. The best data on this come from diet and surgery studies, not GLP-1 studies.

What the neck-fat studies show

The CENTRAL trial gives the most detailed measurements. In this RCT of 278 adults (90% men), whole-body MRI tracked fat depots over 18 months of dieting. Neck (cervical) fat fell 13.1% and chin fat fell 5.3% at 6 months, and fat changes tracked weight loss (r≈0.7) (Tsaban et al., 2021). The trial was publicly funded (German, Israeli and US Veterans Affairs grants). Evidence: limited (diet, not GLP-1).

A smaller study complicates that picture. In a prospective 3D face-scanning study of 23 people, scanned before and 6 months after bariatric surgery, mean neck volume loss was about 75 ml. Total weight loss and neck volume loss were not significantly correlated (Peters et al., 2020). The study was run at RWTH Aachen, an academic center. Evidence: early / preliminary (n=23).

Taken together, these two studies suggest neck fat shrinks with weight loss, but how much varies from person to person. Neither study tells you how quickly your own neck will change.

Does the face change too?

Ozempic neck often shows up alongside facial volume loss, but the only GLP-1 imaging study measured the midface, not the neck (Sharma et al., 2025). For cheeks and midface, see our guide to what causes Ozempic face and what can help. We found no study supporting the claim that "the neck shows changes before the face," so we don't repeat it.

Is Ozempic neck the same as turkey neck?

Ozempic neck and "turkey neck" describe the same visible signs, loose skin under the chin and down the front of the neck, but with a different trigger. Turkey neck is the everyday name for central neck laxity that comes with aging. Ozempic neck describes that look appearing after rapid GLP-1 weight loss. A 2024 systematic review linked massive weight loss from any cause with central neck skin laxity (Jafar et al., 2024). Evidence: limited.

What parts of the neck change with Ozempic neck?

Ozempic neck can involve four separate things, and each responds to different treatments. Telling them apart is why an in-person exam matters:

No study has measured any of these features in GLP-1 users. The table describes standard anatomy and the treatments clinicians typically discuss, not tested outcomes.

Does semaglutide damage neck skin directly?

No human study we found shows that semaglutide or tirzepatide directly damages skin collagen or elastin. The skin-structure data come from people who lost weight after bariatric surgery, and they measured abdominal or breast skin, not the neck.

Collagen is the main structural protein in the dermis, the skin's middle layer. Elastin is the protein that lets skin recoil. In a controlled histology study comparing 40 women after bariatric surgery with 40 women who had never had obesity, abdominal skin after weight loss had less collagen, but elastic fibers were not damaged (Orpheu et al., 2010). Evidence: limited.

A 2024 study of 80 biopsies compared surgical with non-surgical massive weight loss. The only difference it found was more dermal elastin in the abdominal skin of the non-surgical group. Other collagen and elastin measures did not differ (Hany et al., 2024). The authors declared no competing interests. Evidence: limited.

A recurring claim in GLP-1 communities is that the drug itself "eats collagen." The biopsy data above describe weight loss, not a drug effect, and none of it involves neck skin.

Does Ozempic neck make you look older?

People with Ozempic neck-type changes may be judged as looking older after major weight loss, but not always as less attractive. Both findings come from small bariatric-surgery studies.

• Looking older: 7 facelift patients who had lost more than 100 lb were rated by 40 blinded raters as looking 5.1 years older than their actual age before surgery, compared with 11 controls (Couto et al., 2015). Evidence: early / preliminary.
• But often more attractive: In photos of 14 bariatric patients rated by about 100 survey respondents, people were rated older but more attractive after substantial weight loss. Only 5 of the 14 had a significant change in perceived age (Papoian et al., 2015). Evidence: early / preliminary.

Neither study isolated the neck, and neither involved GLP-1 medications.

Does Ozempic neck go away after your weight stabilizes?

We don't know. No study has followed neck or jawline appearance in GLP-1 users after their weight stabilized or after they stopped the drug.

The weight-regain data exist, but they don't tell you anything about appearance. In the STEP 1 extension, people who stopped semaglutide regained 11.6 percentage points of their earlier weight loss by week 120, about two-thirds of what they had lost (Wilding et al., 2022). Nobody measured whether neck or facial fat returned along with the weight.

A common pattern in GLP-1 forums is people who have held a steady weight for months and say their face and jawline haven't "filled back in." That's anecdote, not evidence, but it's a reason to be skeptical of any claim that volume reliably returns.

Can skincare help Ozempic neck?

Skincare cannot replace lost fat, and no topical product has been tested in GLP-1 users. Neck-specific skincare studies were done in people who weren't on these drugs, so treat any benefit as general neck-aging care, not a fix for GLP-1 changes.

What the neck-specific skincare evidence covers

Sullivan et al. (2023) tested a neck cream combining retinol, a tripeptide and glaucine in two clinical trials and reported significant improvement in neck lines, crepiness, laxity and texture after 12 to 16 weeks (Sullivan et al., 2023). Retinol is a vitamin A derivative, part of the retinoid family. Keep three caveats in mind:

1. Industry authors. The authors are from L'Oréal Research & Innovation and SkinCeuticals, a L'Oréal brand, so this is an industry study.
2. No GLP-1 users. Participants were not taking GLP-1 medications.
3. Missing numbers. The abstract does not give the sample size or effect sizes, so we don't quote them.

Evidence: limited (single industry study, not in GLP-1 users).

If you try a retinoid on your neck, start gradually and stop if irritation develops. Neck skin is often more reactive to retinoids, and a dermatologist can help with product choice.

Where peptides fit

Copper peptides such as GHK-Cu (a copper-binding tripeptide) and signal peptides are popular in neck creams. Most of the supporting evidence is lab work or small, often manufacturer-linked trials, and none of it was done in GLP-1 users. See our review of copper peptide research for what has and hasn't been tested. If you use one, think of it as general skincare with limited evidence, not as a treatment for Ozempic neck.

A reasonable, low-risk neck routine

Nothing below has been studied in GLP-1 users. The goal is to treat your neck the way you already treat your face:

Our step-by-step skincare protocol covers layering and order.

What about collagen supplements and diet?

Oral collagen hasn't been tested for neck changes in GLP-1 users. Our collagen supplement review found that apparent skin benefits shrink or disappear in trials not funded by industry.

Adequate protein matters for overall health during weight loss, especially when appetite is low. No study links a specific protein intake to neck or facial skin outcomes on GLP-1s, so ask your clinician or a registered dietitian what makes sense for you.

What professional treatments are used for Ozempic neck?

Clinicians use injectables, energy devices and surgery, but none of these has been tested specifically on the neck in GLP-1 users. The available data are one uncontrolled, manufacturer-funded jawline-and-face study, expert opinion and small registered trials without results.

Injectables at the jawline

The Lorenc 2026 study is the largest GLP-1-specific aesthetic study so far. It was a multicenter, open-label study (no control group) of 41 people who had lost weight on GLP-1 medications. Participants received 2–3 sessions of Sculptra and 1–2 sessions of Restylane Lyft or Contour and were followed for 9 months (Lorenc et al., 2026; NCT06351358):

• Product types: Sculptra is poly-L-lactic acid (PLLA), a biostimulator, meaning an injectable meant to trigger the body's own collagen production. Restylane products are hyaluronic acid (HA) fillers, gels that add volume directly.
• Results: Cheek, jawline and perioral contour improved, along with skin quality. 91.4% of participants said they would recommend the regimen, and no treatment-related adverse events were reported.
• Funding: Galderma, which makes both products, funded the study, designed it and analyzed the data. Four co-authors were current or former Galderma employees.
• Scope: The neck itself was not a treatment area.

Evidence: limited (manufacturer-funded, uncontrolled).

The fuller picture on fillers is in our article on dermal fillers for Ozempic face.

Expert opinion on timing and approach

A 2026 expert consensus from 4 clinicians states that aesthetic treatments "have not yet been widely studied in this population." It says timing within the weight-loss journey should be considered and favors combining HA fillers with biostimulators (Moradi et al., 2026). Allergan Aesthetics (AbbVie) funded the writing support, one author is an Allergan employee, and the lead author consults for several filler makers. No trial has compared treatment timing. Evidence: expert opinion.

A 2023 narrative review describes fillers, skin-tightening procedures and surgery as options and notes that prescribers "seldom counsel" patients about facial changes (Humphrey et al., 2023). The authors declared no conflicts. Evidence: expert opinion.

Energy devices and surgery

Radiofrequency (RF) microneedling uses fine needles to deliver heat energy into the dermis. In a prospective study at University Medical Center Hamburg-Eppendorf, 30 patients (mean age 55.5) had 1 to 3 RF microneedling sessions on the lower face, jawline and neck. Submental volume fell by a mean 4.72 cm³, but results ranged from a 26.65 cm³ loss to a 16.01 cm³ gain, and mean pain was 5.6 out of 10 (Nguyen et al., 2022). Participants were not GLP-1 users, and the study had no separate control group. Evidence: limited (not in GLP-1 users).

A pattern in GLP-1 forums is people saying their injectors steered them away from filler for true neck sagging, toward energy devices or surgical consultation. That fits the expert view that volume products restore volume, not loose skin (Humphrey et al., 2023). Only an in-person exam can tell you which applies to you.

Trials underway

Every GLP-1 aesthetic trial we found on ClinicalTrials.gov is small (n≤48) and injectable-focused, and none has reported results. None targets the neck:

We found no registered trial of any topical skincare product in GLP-1 users.

We have left out treatment prices and recovery timelines because we couldn't find a dated, sourced cost survey or trial data to support them. Ask providers for written quotes.

Is neck skin pain or burning part of Ozempic neck?

No. Skin that hurts, burns or feels sunburned without a rash is a separate, label-listed side effect called dysesthesia, a nerve-related change in how the skin senses touch. It isn't caused by sagging or fat loss.

In the STEP UP trial, a Novo Nordisk-sponsored, double-blind RCT of 1,407 adults over 72 weeks, dysesthesia was reported by 22.9% of people on semaglutide 7.2 mg, 6.0% on 2.4 mg and 0.5% on placebo (Wharton et al., 2025). The current Wegovy label lists dysesthesia at 2% vs 1% placebo in the 2.4 mg weight-reduction trials, and at 22% on 7.2 mg vs 6% on 2.4 mg and 0% on placebo (Wegovy prescribing information, DailyMed, revised 06/2026). Evidence: well-established as a label-listed reaction.

If your neck skin hurts, tell your prescriber rather than reaching for a new cream. Our Mounjaro skin sensitivity article covers this in more detail.

What do FDA adverse event reports show about Ozempic neck?

FDA adverse event reports barely capture Ozempic neck. "Skin laxity" appears in only a few dozen reports, likely because people don't think of a cosmetic change from weight loss as a drug reaction.

How we got this data: We queried the openFDA drug adverse event endpoint (FAERS, the FDA Adverse Event Reporting System) on Oct 10, 2026, at 2:29 PM CT. Each search combined a generic name (semaglutide or tirzepatide) with an exact MedDRA preferred term, a standardized medical vocabulary for reactions, e.g. this skin laxity query for semaglutide. Counts include any report listing the drug, as either a suspect or a concomitant drug.

Source: openFDA FAERS, queried Oct 10, 2026.

FAERS reports are voluntary and unverified. A report means someone linked a symptom to a drug, not that the drug caused it. FAERS reports show what patients and clinicians reported while on a drug. They don't show that the drug caused the event, and they can't be used to estimate how often it happens. Counts also rise with the number of people using a drug and with media attention, and they include duplicates and have no denominator, so they can't be used to compare risk between semaglutide and tirzepatide.

When should you see a clinician about Ozempic neck?

See a clinician if neck changes bother you, if you have skin pain or burning, or if you're considering any procedure. A board-certified dermatologist or plastic surgeon can examine you and tell you whether you're dealing with lost volume, loose skin or both.

Questions worth asking:

• Is my main issue volume loss, skin laxity or muscle banding?
• What evidence supports this treatment for the neck specifically, and was any of it in GLP-1 users?
• Who funded that evidence?
• Should I wait for my weight to stabilize? (No trial has answered this, per Moradi et al., 2026.)

Questions about your dose or pace of weight loss belong with your prescriber, not your injector. No study shows that a slower dose increase protects neck skin.

Where the evidence stops

• No neck measurements in GLP-1 users. All neck-fat data come from diet (Tsaban 2021) and bariatric-surgery (Peters 2020) studies.
• No direct drug-on-skin data. No human study shows that semaglutide or tirzepatide itself changes skin collagen or elastin.
• No topical trials. No skincare product, peptide or otherwise, has been tested in GLP-1 users, and none is registered on ClinicalTrials.gov.
• No controlled injectable trials. The one sizable GLP-1 study (n=41) was uncontrolled, manufacturer-funded and didn't treat the neck.
• No recovery data. We don't know whether neck changes improve after weight stabilizes, after stopping the drug, or with regain.
• No timing data. Advice on when to start treatment is expert opinion.

FAQ

Does Ozempic neck go away on its own? We don't know. No study has tracked neck appearance after GLP-1 weight loss stabilizes or after stopping. People in the STEP 1 extension regained about two-thirds of their lost weight within a year of stopping, but nobody measured their necks (Wilding et al., 2022).

Can you prevent Ozempic neck while taking a GLP-1 medication? No method has been shown to prevent it. Neck fat loss accompanies weight loss in diet studies (Tsaban et al., 2021), and no topical or supplement has been tested in GLP-1 users. Sunscreen and a gentle routine are low-risk general care, not proven prevention.

Does Mounjaro or Zepbound cause neck sagging too? Any substantial weight loss can change the neck, whatever the drug. No study compares neck or facial changes between tirzepatide and semaglutide, and FAERS counts can't answer that question.

Will fillers or Sculptra fix Ozempic neck? There's no GLP-1 study of neck treatment. The largest GLP-1 study treated the cheeks and jawline, had no control group and was funded by Galderma (Lorenc et al., 2026). For loose skin rather than lost volume, clinicians often discuss energy devices or surgery instead (Humphrey et al., 2023).

Is Ozempic neck different from normal neck aging? The visible signs overlap, and reviews of weight loss from any cause describe central neck laxity (Jafar et al., 2024). What's different is the cause: fat loss, not years of aging alone. Whether skin behaves differently after GLP-1 weight loss than after diet or surgery hasn't been studied.

Is Ozempic neck the same as turkey neck? Ozempic neck and turkey neck share the same signs, loose skin under the chin and along the front of the neck. The difference is the trigger: turkey neck usually describes aging, while Ozempic neck describes that look after rapid GLP-1 weight loss (Jafar et al., 2024).

Why do neck bands look more visible after losing weight? Vertical neck bands are the edges of the platysma muscle. When the fat over the neck thins, those edges can show more. No study has measured neck bands in GLP-1 users, so ask a clinician to assess them.

Do neck creams work for Ozempic neck? No neck cream has been tested in GLP-1 users. One industry-run study of a retinol, tripeptide and glaucine neck cream reported improvement in crepiness and laxity in general neck aging after 12 to 16 weeks (Sullivan et al., 2023).

Should I lower my dose to protect my neck skin? Never stop, skip or change a GLP-1 medication for skincare reasons. Talk to your prescriber first. No study shows that a lower dose or slower titration protects the neck.

References

1. Peters F, et al. [Prospective 3D facial surface scans before and 6 months after bariatric surgery]. J Craniomaxillofac Surg. 2020. Prospective cohort, n=23; academic (RWTH Aachen). https://pubmed.ncbi.nlm.nih.gov/32513431/
2. Tsaban G, et al. [CENTRAL trial: diet-induced changes in body fat depots by whole-body MRI]. Nutrients. 2021. RCT, n=278, 18 months; public grants. https://pubmed.ncbi.nlm.nih.gov/34836081/
3. Jafar, et al. [Systematic review of facial aging after massive weight loss]. Aesthet Surg J Open Forum. 2024. Systematic review, 13 studies + 1 abstract; funding not reported. https://pubmed.ncbi.nlm.nih.gov/39346804/
4. Sharma, et al. [Midface volume change on CT/MRI after GLP-1 prescription]. Otolaryngol Head Neck Surg. 2025. Retrospective cohort, n=20; funding not reported. https://pubmed.ncbi.nlm.nih.gov/40407186/
5. Couto RA, et al. [Perceived age in facelift patients after massive weight loss]. Aesthetic Plast Surg. 2015. Retrospective, 7 cases vs 11 controls, 40 raters. https://pubmed.ncbi.nlm.nih.gov/26311559/
6. Papoian, et al. [Perceived age and attractiveness after bariatric weight loss]. Arch Plast Surg. 2015. Photo survey, 14 patients, ~100 raters; no COI. https://pubmed.ncbi.nlm.nih.gov/26430627/
7. Orpheu SC, et al. [Collagen and elastic fibers in skin after bariatric surgery]. Obes Surg. 2010. Controlled histology, 40 vs 40; academic. https://pubmed.ncbi.nlm.nih.gov/19937152/
8. Hany, et al. [Skin histology after surgical vs non-surgical massive weight loss]. Obes Surg. 2024. 80 biopsies; no competing interests. https://pubmed.ncbi.nlm.nih.gov/38277086/
9. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. RCT, 68 weeks; Novo Nordisk. https://pubmed.ncbi.nlm.nih.gov/33567185/
10. Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy (STEP 3). JAMA. 2021. RCT; Novo Nordisk. https://pubmed.ncbi.nlm.nih.gov/33625476/
11. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022. Extension to week 120. https://pubmed.ncbi.nlm.nih.gov/35441470/
12. Lorenc ZP, et al. [PLLA-SCA plus HA filler after GLP-1 weight loss]. Aesthet Surg J. 2026. Open-label, uncontrolled, n=41, 9 months; funded by Galderma; NCT06351358. https://pubmed.ncbi.nlm.nih.gov/41243519/
13. Moradi A, et al. [Expert consensus on aesthetic treatment after GLP-1 weight loss]. Aesthet Surg J Open Forum. 2026. Consensus, 4 clinicians; writing support funded by Allergan Aesthetics. https://pubmed.ncbi.nlm.nih.gov/41768029/
14. Humphrey CD, et al. [Narrative review of "Ozempic face"]. Facial Plast Surg. 2023. Narrative review; none declared. https://pubmed.ncbi.nlm.nih.gov/37541662/
15. Sullivan K, et al. Evaluation of a retinol containing topical treatment to improve signs of neck aging. J Cosmet Dermatol. 2023. Retinol + tripeptide + glaucine; two trials, 12–16 weeks; industry authors (L'Oréal/SkinCeuticals); not GLP-1 users. https://pubmed.ncbi.nlm.nih.gov/37461826/
16. Nguyen L, et al. Radiofrequency Microneedling for Skin Tightening of the Lower Face, Jawline, and Neck Region. Dermatol Surg. 2022. Prospective, n=30; academic (Hamburg); not GLP-1 users. https://pubmed.ncbi.nlm.nih.gov/36449871/
17. Wharton S, et al. [STEP UP: semaglutide 7.2 mg vs 2.4 mg vs placebo]. Lancet Diabetes Endocrinol. 2025. Double-blind RCT, n=1,407, 72 weeks; Novo Nordisk. https://pubmed.ncbi.nlm.nih.gov/40961952/
18. Daneshgaran G, et al. [Systematic review of GLP-1 facial changes and Google Trends]. Aesthet Surg J Open Forum. 2025. Systematic review, 23 articles; no funding or conflicts declared. https://pubmed.ncbi.nlm.nih.gov/40626110/
19. Wegovy (semaglutide) prescribing information. DailyMed, SPL v19, revised 06/2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
20. US FDA. openFDA drug adverse event (FAERS) API, queried Oct 10, 2026. https://api.fda.gov/drug/event.json

Disclosure: This article is for general information only and is not medical advice. Peptide Skincare Editorial Team does not hold clinical credentials, and this article has not been reviewed by a clinician. Never stop, skip or change a GLP-1 medication for skincare reasons. Talk to your prescriber first. For any treatment decision, consult a qualified clinician. This article contains no affiliate links.

For educational purposes only; not medical advice. See our disclaimer and research method.